With the beginning of the Human Genome Project, an emerging field of science was brought to the forefront of the pharmaceutical community. Pharmacogenetics facilitates optimization of the current patient-centered care model and pharmacotherapy as a whole. Utilizing these ever-expanding branches of science to nonsteroidal anti-inflammatory drugs (NSAIDs) can provide novel opportunities to affect patient care. With a wide range of NSAID choices available as treatment options for relieving pain and/or reducing inflammation or fever, a more systematic way of selecting the ideal agent for the patients based upon their genetic information could spare them from a potentially permanent health-care condition. Furthermore, if a patient possesses or lacks certain alleles, serious adverse events can be anticipated and avoided. The tailoring of drug therapy can be achieved using the published data and cutting-edge genetic testing to attain a higher standard of care for patients.
INTRODUCTION
Pharmacogenetics is the study of the genetic factors influencing variation in drug metabolism and response. 1 The completion of the human genome project facilitated the study of variable drug effects based on individual genetic make-up. 2 The human genome project has identified numerous types of genetic variations among individuals that may or may not alter drugs effects. The genetic variations are either classified as polymorphisms or mutations. 3 A polymorphism is defined as variation in a DNA sequence that occurs at a frequency of at least 1% in the human population, whereas a mutation occurs in o1%. There are many factors influencing whether or not a polymorphism will result in a change in function of the protein the gene codes for, most importantly being the region of the gene the polymorphism occurs on. 4 More than 90% of human genes possess a minimum of one singlenucleotide polymorphism (SNP), and the vast majority of every human gene is marked by a sequence variation. More than 14 million SNPs have currently been identified from the human genome. More than 60 000 SNPs have been located in the coding regions of the genes. 5 Genetic variations can cause a wide range of variability in pharmacokinetic profile of drugs, resulting in differences in efficacy and toxicity profiles of pharmaceuticals. This can be due to genetic differences in the proteins involved in drug elimination or drug targets. Pharmacogenetics allows for optimization of pharmacotherapy based upon the patient's respective genetic make-up. 6 Nonsteroidal anti-inflammatory drugs (NSAIDs) ( Table 1) are the commonly prescribed medications, with an estimated 70 million number of prescriptions annually written and $6.8 billion spent worldwide in the attainment of this drug class. 7, 8 The therapeutic and sides effect of NSAIDs are caused by decreased production of prostaglandins. 9 NSAIDs inhibit the ability of cyclooxygenase (COX) to produce prostaglandins from arachidonic acid, subsequently leading to a decreased amount of inflammation experienced by most patients. Currently, there are two identified isoforms of COX. 10 COX-1 is constitutively present in many tissues throughout the body and COX-2 is expressed in response to injury or inflammation. 11 NSAIDs are divided into two broad categories based on their selectivity for COX: nonselective NSAIDs and COX-2-selective inhibitors. NSAIDs are indicated as analgesics, anti-inflammatory and antipyretic agents in numerous conditions.
The commonplace side effects that are manifested in patients receiving NSAIDs can include gastrointestinal tract ramifications. The gastrointestinal side effects can range from stomach upset to fatal-diaphragm-like colonic strictures. 12 Other side effects of NSAIDs include renal abnormalities such as hyperkalemia, acute renal failure, hypernatremia, compromised glomerular filtration rate and edema. 13, 14 It is crucial to understand the pharmacogenetics/pharmacogenomics of NSAIDs in order to best treat patients with the most appropriate agents that will have enhanced therapeutic outcomes with fewer side effects. Although not all NSAIDs would realistically benefit from pharmacogenetic testing, several NSAIDs demonstrate variable drug response based upon various genetic polymorphisms of metabolizing enzymes. For instance, the metabolism of several NSAIDs (for example, celecoxib, diclofenac and ibuprofen) depends on CYP2C9. 15 This enzyme can have heterozygous and homozygous variant genotypes, such as CYP2C9*2/*2 and CYP2C9*1/*3. CYP2C9*2 and CYP2C9*3, two of the more common variant alleles, have been extensively studied. [16] [17] [18] [19] Genetic testing for these specific variances in alleles would aid in determining if a medication will be a valid pharmacotherapeutic option for a specific patient. For example, there appears to be a demarcation in the enzymatic function because of the fact that *1*1 genotype exists in 96% of the Chinese and Japanese populations, whereas heterozygous CYP2C9*1/*3 boasts 4% of these two populations. 20 This could subsequently aid a physician's or prescriber's choice of a drug therapy regimen that can increase efficacy while simultaneously decreasing adverse effects, similar to the concern of certain HMG-CoA (3-hydroxy-3-methylglutaryl-coenzyme A) reductase inhibitors ('statins') in Asians. 21 This article discusses major NSAIDs with relation to their known pharmacogenetics and possible application for their clinical use.
DIARYL HETEROCYCLIC COX-2-SELECTIVE INHIBITORS
COX-2-selective inhibitors can be used for relief of the acute pain associated with dental pain after extraction as well as dosedependent relief from the inflammation accompanying rheumatoid and osteoarthritis.
3 Celecoxib Celecoxib's indications conferred by the Food and Drug Administration (FDA) include the treatment of acute pain, osteoarthritis, rheumatoid arthritis and ankylosing spondylitis. 22 Celecoxib is metabolized via CYP2C9 (estimated at 72-92%). 23 In addition, celecoxib is an inhibitor of CYP2D6. A study conducted by Werner et al. compared the effect of celecoxib and rofecoxib in the metabolism of metoprolol, a substrate of CYP2D6. The study enrolled 12 healthy male subjects; there was a more than 40% increase in the area under the curve (AUC) plasma concentration of metoprolol when used concomitantly with celecoxib as compared with rofecoxib. 24 As stated earlier, celecoxib is extensively metabolized by CYP2C9. 25 An in vitro study utilizing human liver microsomes in addition to yeast microsomes expressing a number of CYP polymorphisms showed that CYP2C9*3 had a lower intrinsic clearance of celecoxib when compared with the wild-type CYP2C9*1 samples. 26 There are conflicting results about whether CYP2C9*2 has a significant decrease in intrinsic clearance. 26, 27 The most marked decrease in metabolism of celecoxib was noted in enzymes expressing homozygous polymorphism CYP2C9*3/*3.
26,27 A corresponding increase in celecoxib's AUC would be expected in individuals expressing CYP2C9*3 allele, and this could result in an increase in dose-related adverse reactions due to accumulation of celecoxib. However, these results are inconsistent with another small group study of nonsmoking Caucasians of both sexes that failed to find a clinically significant difference between the homozygous CYP2C9*3/*3 and the wild type (CYP2C9*1/*1) for patients receiving celecoxib 200 mg twice daily for 15 days. This study assessed blood samples using high-performance liquid chromatography. 28 These conflicting results may be explained by the fact that celecoxib is also metabolized by CYP3A4; individuals with CYP2C9 polymorphisms may experience different pharmacokinetic profiles depending on their CYP2C9/CPY3A4 ratio. 27 Furthermore, in addition to the ratio of enzymes, there might be a corrective shift from one enzymatic pathway to another that might become saturated leading to the compromising mechanism failing to maintain an adequate level of drug elimination. However, it is still patient specific as to whether this would be consistent with greater efficacy or with an increased incidence and severity of the adverse events. These adverse events could include an increased propensity for renal impairment or other dose-related side effects. 29 Chan et al. 30 reported the efficacy and safety of low (200 mg, twice daily) and high (400 mg, twice daily) doses of celecoxib in 1660 patients genotyped wild type, CYP2C9*2 or CYP2C9*3. A protective effect (a reduction in adenoma) of celecoxib was observed in subjects genotyped wild type or variant and who received low or high doses of celecoxib as compared with patients who received placebo. But, an additional benefit of high dose was demonstrated only in the subjects with CYP2C9*3 genotype. Although the cardiovascular adverse events were observed in wild-type genotyped subjects who received low or high dose of celecoxib, the events were reported only in variant genotyped subjects who were administered high doses of the drug. 30 A clinical study conducted by Tang et al. 27 measured celecoxib concentrations in plasma samples after a single oral dose. CYP2C9*1/*3 and CYP2C9*3/*3 genotypes demonstrated higher values of AUC compared with subjects with wild-type genotypes. There were lower concentrations of carboxy-celecoxib and hydroxyl-celecoxib in heterozygous and homozygous CYP2C9*3 allele carriers as well. 29 These data help to support the hypothesis that CYP2C9 polymorphisms affect the variability in the pharmacokinetics of celecoxib. 26 Celecoxib exerts its effect by inhibition of COX-2, which is encoded by the prostaglandinendoperoxide synthase 2/COX-2 (PTGS2) gene. In a small study of 20 healthy individuals, Skarke et al. 31 examined the effect of a SNP (_765G_C) in the PTGS2 gene on the inhibitory effect of celecoxib or the expression of COX-2 enzyme. The participants included carriers of the wild-type allele (_765GG) and variant allele (_765CC) and received a single dose of celecoxib (200 mg). The investigators did not find any significant difference in terms of COX-2 expression and inhibitory effect between wild-type and variant genotype groups.
Lumiracoxib
Lumiracoxib is approved in multiple countries outside the United States and was deemed 'not approvable' by the FDA because of liver toxicity concerns. 32 This COX-2 inhibitor was developed for the treatment of osteoarthritis and acute pain. The trial utilized for the approval process was the Therapeutic Arthritis Research and Gastrointestinal Events Trial (TARGET). 33, 34 This trial enrolled more than 18 000 subjects Z50 years of age who suffered from osteoarthritis. An independent case-control genome-wide association trial was conducted utilizing the patients from the TARGET trial. It was a retrospective analysis utilizing a genome scan on 41 lumiracoxib-treated subjects with liver injury and 176 lumiracoxibtreated control subjects. 32 The analysis revealed a large number of SNPs from chromosome 6, showing an association with rs9270986 as the SNP with the lowest P-value (P ¼ 2.8 Â 10 À 10 ). A total of seven SNPs, exclusively mapped to the major histocompatability complex (MHC) class II region, maintained statistical significance following genome-wide multiple-testing correction. Furthermore, these SNPs possessed association with lumiracoxib-related liver enzyme elevation from the TARGET trial. The study was able to reproduce the MHC class II region results utilizing 98 lumiracoxibtreated cases and 405 matched lumiracoxib-treated controls. Interestingly, the HLA-DQA1*0102 allele's sensitivity improved coinciding with the liver enzyme elevation thresholds. These corresponding events help highlight the importance of pharmacogenetic utilization with some pharmacotherapeutic options.
SALICYLATES

Acetylsalicylic acid
Acetylsalicylic acid (aspirin) is rapidly hydrolyzed to salicylic acid, and exerts anti-inflammatory effects by irreversibly inhibiting both isoforms of COX, COX-1 and COX-2.
35 COX-1 is the predominate form of the COX enzyme found in platelets, and patients with the COX-1 G allele A842G polymorphism have shown a decreased response to aspirin, together with patients demonstrating C13254T polymorphism of the GP VI platelet receptor, a receptor responsible for subsequent activation of platelets in the clotting cascade. 36 Aspirin prompts a lifespan defect in platelets; this is clinically detectable as a prolongation of the bleeding time for patients receiving aspirin. This effect appears to be principally related to the permanent inactivation of COX. 3, 37 Of the two isoenzymes of COX, type 1 is constitutively expressed in most tissues and is involved in the synthesis of the prostaglandins and thromboxane A 2 .
Patients possessing polymorphisms may not experience the expected therapeutic effect upon receiving aspirin. This might precipitate the patient requiring more aspirin than is typically utilized, resulting in an increased propensity for renal and gastrointestinal adverse effects. A small cross-sectional study observed a faster in vivo conjugation of salicylic acid in patients genotyped UGT1A6*2/*2 than in the wild-type UGT1A6*1/*1. 38 The faster conjugation may subsequently influence the therapeutic response to aspirin; however, the study was limited by its design and small number of participants, and more study designs with larger populations should be conducted to make a more definitive conclusion. Clinically speaking, with the low cost of various aspirin products and the relative high cost of pharmacogenetic testing, applicability of testing would not be applicable for most patients.
ACETIC ACID DERIVATIVES
The acetic acid derivatives possess higher potency than that of aspirin.
3 Diclofenac Diclofenac's foremost route of metabolism uses CYP2C9 forming 4'-hydroxidiclofenac. 16 Various CYP2C9 polymorphisms have been studied to determine whether they possess a negative effect on diclofenac's pharmacokinetics resulting in increased toxicities. To date, studies have shown that different CYP2C9 alleles do not seem to elicit a clinically significant effect of the pharmacokinetic parameters or hepatic toxicity correlated with the metabolism of diclofenac. 16, 17, 28 In addition to the pharmacogenetics of diclofenac, it has been theorized that this NSAID binds differently to the CYP2C9 enzyme irrespective of the pharmacogenetics variation possessed by a patient. This may affect some of the pharmacokinetic data that have been gathered for diclofenac. 18 Indomethacin Indomethacin can be used for closure of patent ductus arteriosus in premature infants. 22 Indomethacin is metabolized by CYP2C9 and carboxy esterase (minor pathway). 19 One study assessed the clearance of indomethacin and observed the role of CYP2C9 and CYP2C19, and noted that there was a 16-fold higher difference when assessing the role of CYP2C9 in comparison with that of CYP2C19 when clearing this NSAID. 39 Researchers have assessed the role of CYP2C9 in the overall clearance of indomethacin and have determined that its role is substantial regarding the clearance of indomethacin. 40 There was no significant difference in the AUC for indomethacin in patients experiencing gastrointestinal bleeding compared with those without bleeding. 41 An additional study assessed the frequency of the CYP2C9 variation among 20 þ individuals with a past medical history of NSAIDrelated gastric ulceration versus 30 þ individuals who did not have a history of gastropathy. 42 The ensuing frequency of CYP2C9*1/*1 (wild-type) genotype was similar to that possessed by subjects with a history of gastric ulcers associated with NSAID use and those receiving NSAIDs without the gastric ulceration. Additionally, the two other genotypes identified in the small study were both heterozygous genotypes, CYP2C9*1/*2 and CYP2C9*1/*3. There was no statistically significant difference between either of the two groups, which would weaken the case for a pharmacogenetics difference accounting for the past medical history of gastrointestinal ulcerations. It was determined that there were no homozygous genotypes (CYP2C9*2/*2 and CYP2C9*3/*3) identified in this study, and this may limit the applicability of the study to the NSAID-taking population as a whole because of the inexhaustive patient population. Thus, based upon the evidence available, pharmacogenetic testing for indomethacin would not be as clinically useful as other NSAIDs (for example, lumiracoxib) because of lack of relationship between CYP2C9 variants and adverse events.
PROPIONIC ACID DERIVATIVES
Propionic acid derivatives are COX nonselective inhibitors. Propionic acid derivatives enjoy approvals for rheumatoid and osteoarthritis, in addition to pain, and primary dysmenorrhea. 3 
Flurbiprofen
Flurbiprofen is an organic acid 43 that is metabolized by CYP2C9 forming 4 0 -hydroxiflurbiprofen. 18 Interestingly, flurbiprofen is a medication that is used in the assessment of CYP2C9 variations and pharmacokinetic ramifications. 43 A typical hyperbolic profile metabolism is displayed for CYP2C9*3 and CYP2C9*5, in addition to the wild-type CYP2C9*1. CYP2C9*3 and CYP2C9*5 alleles showed a diminished formation of 4 0 hydroxiflurbiprofen, higher Michaelis-Menten constant (K m ) and lower maximum velocity (V max ), with CYP2C9*5 having a more pronounced difference when compared with CYP2C9*1.
18 A 2003 study assessed the effect of the variation of CYP2C9*1/*1 versus *1/*2 versus *1/*3 for flurbiprofen. The results showed that the AUC was higher with a simultaneous decrease in clearance for the CYP2C9*1/*3 group compared with the CYP2C9*1/*1 group. 44 A pharmacokinetic study published in 2011 was performed in 22 male Pakistanis that further justifies that more data are required for the elucidation of pharmacogenetics role for this medication. This study showed a difference in metabolism of flurbiprofen for one of the subjects in comparison with the other 21 male subjects, hinting at an interindividual basis for this difference. 45 Ibuprofen Ibuprofen undergoes extensive hepatic metabolism, mainly into either hydroxylate or carboxylate derivatives. 3 Ibuprofen is a nonselective inhibitor of COX-1 and COX-2. Many commercially available formulations include a racemic mixture of R-( À ) and S-( þ ). Following administration of racemic ibuprofen, B60% of the R-( À ) enantiomer is converted to the S-( þ ) enantiomer, the more potent inhibitor of COX-1 and COX-2. 46, 47 Data from previous biochemical studies indicate that CYP2C8 and CYP2C9 may be the S-ibuprofen hydrolase, in contrast to R-ibuprofen being primarily metabolized by CYP2C8. 48, 49 There are at least three clinically relevant alleles of CYP2C9 in Caucasian populations, and each allele confers different activity. 50 The wild-type allele, also known as CYP2C9*1, possesses an arginine at codon 144 and an isoleucine at codon 359. The CYP2C9*2 variant substitutes a cysteine in lieu of arginine at codon 144. The CYP2C9*3 variant contains leucine in lieu of isoleucine at codon 359. 50 Ibuprofen-facilitated inhibition of the COX-1 and COX-2 is influenced by the CYP2C9 genotype. Compromised clearance of racemic mixture ibuprofen in addition to (S)-ibuprofen were experienced by carriers of the two CYP2C9*3 alleles. Applying this pharmacokinetic knowledge to the clinical setting may influence clinicians to anticipate an increase in the pharmacodynamic potential of ibuprofen in patients possessing those specific variants. 50 According to in vitro data and pharmacokinetic studies, the activity provided by CYP2C9*2 is slightly less than the activity of the wild-type allele. 51 However, CYP2C9*3 confers roughly 10 to 30% of the enzymatic activity of the wild type, depending on the substrate being studied. [51] [52] [53] [54] Genomic factors play a role in the extent to which ibuprofen is eliminated from the body. A study published in 2004 comparing the role of CYP2C8 and CYP2C9 polymorphisms in pharmacokinetic profile of ibuprofen noted a significant difference in the clearance of ibuprofen when comparing CYP2C8*1/*1 (4.04 l h ). 55 There was a similar effect of ibuprofen for the CYP2C9 polymorphism, especially pertaining to the inhibition of COX-1. Pharmacodynamic activity was assessed using ex vivo thromboxane B2 formation. The authors concluded that diminished S-( þ ) enantiomer clearance and increased pharmacodynamic activity may affect patients receiving ibuprofen. 50 An additional ramification of decreased activity of the CYP2C9*2 and CYP2C9*3 alleles can include an increase in the concentrations of NSAIDs in patients, inadvertently manifesting itself as an acute upper gastrointestinal bleeding. 56 This understanding helped initiate a prospective study seeking to determine whether the frequency of the CYP2C9*3 allele would be overrepresented among patients treated with non-aspirin NSAIDs in comparison with the frequency of the CYP2C9*3 allele for patients on aspirin would be comparable to the general population's frequency. 57 The non-aspirin NSAID group, in addition to ibuprofen, included ketoprofen, diclofenac, piroxicam, meloxicam, tenoxicam and rofecoxib. To assist in the determination of an odds ratio for acute upper gastrointestinal bleeding, the investigators analyzed patients with NSAID-related acute upper gastrointestinal bleeding. Aspirin was not appreciably metabolized by CYP2C9, whereas non-aspirin NSAIDs are to differing degrees metabolized by CYP2C9. Based upon the data collected, the hypothesis concerning the frequencies was justified. The frequency of the CYP2C9*3 allele was 3.7 times greater in the non-aspirin group than in the aspirin group (odds ratio 5, 95% confidence interval 2.2-11.1, P ¼ 0.0001). 57 Naproxen Naproxen is indicated for juvenile and rheumatoid arthritis, osteoarthritis, tendonitis and acute gouty attacks. 22 Naproxen sodium is metabolized by the liver enzyme CYP2C9 forming 6-desmethylnaproxen. 25 Like flurbiprofen, the CYP2C9*3 and CYP2C9*5 alleles show a lower clearance when compared with the wild-type CYP2C9*1.
18 However, another study assessed the role of CYP2C9 in the overall clearance of naproxen and concluded that CYP2C9 played a minor role in naproxen clearance, suggesting that pharmacogenetic differences would not be clinically significant if compromised CYP2C9 activity was possessed by a patient taking this medication. 40 Furthermore, there was no significant difference between the C max and AUC for naproxen in patients experiencing gastrointestinal bleeding compared with those without bleeding from two studies. 41, 42 The subsequent frequency of CYP2C9 genotype was comparable to that of subjects with a history of gastric ulcers associated with NSAID use and those receiving NSAIDs minus the gastric ulceration. 41, 42 ENOLIC ACIDS Enolic acids inhibit COX-1 and COX-2 while also possessing antiinflammatory and analgesic action. The enolic acids hold efficacy that is similar to aspirin, indomethacin or naproxen for two specific disease states, rheumatoid arthritis and osteoarthritis. 3 
Piroxicam
The drug is primarily metabolized by CYP2C9. 19 Although a substrate inhibition metabolism is reported for CYP2C9*1 and CYP2C9*3, the CYP2C9*5 metabolism profile was hyperbolic. As the result, the investigators concluded that a single change in amino acid was correlated to a significant change in metabolism of piroxicam. 18 Tenoxicam Tenoxicam is primarily metabolized by CYP2C9. 58 The in vivo clearance of tenoxicam for the CYP2C9 Ile359 to Leu359 variant allele represents o10% of that of the wild-type allele. 59 Vianna-Jorge et al. 58 studied the frequency of CYP2C9*1, CYP2C9*2 and CYP2C9*3 among Brazilians and their influence on the pharmacokinetics of tenoxicam (20 mg). They reported a similar frequency of the examined alleles in Brazilian population compared with that of Caucasians. Also, minimum concentration, maximum concentration and AUC values were higher in the subjects genotyped CYP2C9*1/*3 as compared with those of CYP2C9*1/*1 after repeated doses of tenoxicam. Concerning the influence of the CYP2C9*3 allele on the pharmacokinetics of tenoxicam, the result of this study was in line with the results of another study conducted to examine the influence of CYP2C9 and CYP2C8 alleles on tenoxicam pharmacokinetics. 60 In the latter study, the investigators established a link between the presence of CYP2C9*3 and a change in pharmacokinetic parameters. Altogether, the data support the fact that the pharmacokinetics of tenoxicam is related to the genotype of the individuals taking the drug.
PERSPECTIVES
A considerable amount of data have already been collected concerning the pharmacogenetics of the main metabolic pathways and the major metabolites synthesized for NSAIDs. This, however, is not the case for secondary metabolic pathways and the minor metabolites. The data are very limited and these secondary pathways may seem superficially important; however, this information may be applicable to individuals who are deficient in or have impairment of the metabolizing enzymes for NSAIDs. For example, diclofenac's primary enzyme is CYP2C9, whereas UGT2B7 and a variety of other CYP enzymes are responsible for the secondary metabolism. 19 Additionally, it has been shown that the presence of CYP2C8 variant alleles can cause diclofenac-induced hepatotoxicity 61 in addition to acute gastrointestinal bleeding after the use of NSAIDs. 62 It is worth noting that in addition to polymorphisms in metabolizing enzymes, there are additional genetic factors that may contribute to variable drug response among patients. For instance, in a study assessing acute pain and variation in responses to NSAIDs, researchers examined the gene expression level of the genes encoding enzymes related to production of COX-1 and COX-2 (PTGS1 and PTGS2, respectively) in addition to the genetic polymorphisms and analgesic response to a nonselective NSAID (ibuprofen) or a COX-2-selective inhibitor (rofecoxib) following minor surgery. 63 This study confirmed the wide heterogeneity of gene expression of PTGS1 and PTGS2 among individuals. The COX-1 expression in these patients is marginally diminished, an B36% decrease from baseline values, whereas COX-2 expression was significantly amplified, an B300% increase from baseline values 2-4 h after surgery. The levels of both enzymes returned to baseline values at 48 h after surgery. The effect of ibuprofen or rofecoxib administration on gene expression values at 48 h after minor surgery was an inconsequential detectable change in PTGS1 expression and increased PTGS2 expression. However, the response to analgesic effect of ibuprofen and rofecoxib was opposite and genotype related at 48 h after surgery. The subjects identified as homozygous GG for PTGS2 SNP2 demonstrated a better response to analgesic effect of rofecoxib compared with ibuprofen administration. In contrast, response to ibuprofen was more evident in subjects identified as GC or CC for PTGS2 SNP2. Overall, this study displays that PTGS2 polymorphisms influence the expression of PTGS1 and PTGS1 and consequently analgesic effect of NSAIDs. 63 Also, as previously noted, a genomic-wide study identified multiple SNPs from the MHC II region that revealed an association with the hepatotoxicity of lumiracoxib. 32 The hepatotoxicity is thought to be related to a HLA haplotype. The HLA-DQA1*0102 allele was identified as the most significant allele and a screening marker in lumiracoxib therapy. Clinically, this hepatotoxicity might have been avoided if these genetic markers had been known prospectively before the clinical trials for lumiracoxib were initiated.
Of note, pharmacogenetics is but one patient characteristic, in addition to age, sex, past medical history and other concomitant pharmacotherapy that have to be accounted for when dealing with patients. 64 In addition, many agents comprising mainstream pharmacotherapy would benefit marginally from widespread pharmacogenetics testing because of the cost of the agents. However, certain NSAIDs (foe example, lumiracoxib) may have been able to positively affect patient care with the use of prospective genomic testing to aid in the identification of patients who had a variation in the HLA-DQA1*0102 allele, 32 preventing hepatic impairment and possible hepatotoxicity.
CONCLUSION
NSAIDs are widely used with over 30 million daily users who depend on this class of medications that permits these patients to have relief from the respective ailments that are plaguing them. 19 Their ease of accessibility has created one of the most widely used drug classes for reducing mild to moderate pain. With the advent of the Human Genome Project, there is a new standard that should be sought for understanding how genetic differences in cytochrome enzymes affect the clearance of NSAIDs. The goal of collecting these data is to optimize patient care by selecting effective NSAIDs for each individual, utilizing this class of medications in lieu of analgesics that are either harmful for the patient or ineffective at reducing the pain level experienced by the patient. This aim can be reached through understanding the specific genomics of the patient and the NSAID. However, based upon some of the examples described throughout the article, there appears to be a considerable amount of research, such as retrospective studies modeled after Singer et al., 32 that must be completed to fully understand and ascertain the full mechanism of elimination that is employed when speaking of NSAIDs. These types of studies would help identify associations between genetic markers and adverse effects for patients. This would further allow for pharmacogenetic determinations of adverse effects that patients might experience, and adjusting the dose based on the patient's genotype or choosing other NSAIDs that do not share the same propensity for accumulation. In conclusion, pharmacogenetics is just one tool that should be employed to continue the improvement of patient care by providing analgesia or minimization of pain while avoiding serious side effects such as renal, cardiovascular and gastrointestinal effects.
